Welcome to our dedicated page for Actuate Therapeutics SEC filings (Ticker: ACTU), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Elraglusib’s journey from lab bench to clinic means Actuate Therapeutics’ SEC disclosures are packed with dense data on GSK-3β science, trial cohorts, and cash runway projections—details critical for biotech investors yet hard to digest quickly.
Problem: Finding the latest dose-limiting toxicity update inside a 300-page 10-K or spotting a sudden insider stock sale before a Phase 2 read-out can take hours. Solution: Stock Titan’s AI-powered platform turns every Actuate Therapeutics filing into an executive-level brief. Our engine highlights clinical-trial milestones, R&D spend, and partnership terms, then links them to market-moving events.
Access every document the moment it hits EDGAR: 10-K annual reports, 10-Q quarterly earnings, 8-K material events, S-1 fundraising prospectuses, and real-time Form 4 insider trades. Investors searching for “Actuate Therapeutics insider trading Form 4 transactions” or “Actuate Therapeutics quarterly earnings report 10-Q filing” land here because we answer those questions directly. Want the proxy statement executive compensation breakdown? It’s parsed and summarised. Need “Actuate Therapeutics 8-K material events explained”? Our AI does that, too.
Practical use cases include:
- Monitoring “Actuate Therapeutics Form 4 insider transactions real-time” to gauge management sentiment.
- Reviewing “Actuate Therapeutics earnings report filing analysis” to compare cash burn across quarters.
- Downloading an “Actuate Therapeutics annual report 10-K simplified” to understand pipeline risk factors without legalese.
Actuate Therapeutics (NASDAQ:ACTU) entered a $4.7 million private placement with institutional and accredited investors, selling 666,497 common shares at $7.00 and issuing 666,497 cash-only warrants at the same price. Warrants are immediately exercisable and expire 20 days after an FDA milestone (Breakthrough Therapy designation or Phase 2/3 registration pathway feedback), potentially providing another $4.7 million.
Closing is expected by June 30 2025; proceeds earmarked for working capital. Bios 2024 Co-Invest will hold ~49.9 % beneficial ownership post-deal. A Registration Rights Agreement requires ACTU to file a resale shelf by August 9 2025 and meet strict effectiveness deadlines, with liquidated damages for failure.
- Item 1.01: Securities Purchase & Warrants
- Item 3.02: Unregistered sales under Reg D
- Going-concern risk remains despite new funding.
FAQ
What is the current stock price of Actuate Therapeutics (ACTU)?
What is the market cap of Actuate Therapeutics (ACTU)?
What is the core focus of Actuate Therapeutics Inc?
How does elraglusib work?
What clinical areas does the company target?
What stage of development is Actuate Therapeutics currently in?
How does the company differentiate its approach from conventional cancer therapies?
What are the key benefits of their targeted drug development strategy?
How does Actuate Therapeutics ensure the rigor of its drug development process?
How does Actuate Therapeutics compare with other companies in the oncology space?
